The delta isoform of PI3K predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib

MLA

Villaume, Matthew T., et al. The Delta Isoform of PI3K Predominates in Chronic Myelomonocytic Leukemia and Can Be Targeted Effectively with Umbralisib and Ruxolitinib. Feb. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........6e6d07272d9e40c96b10db5fcc2ad343&authtype=sso&custid=ns315887.

APA

Villaume, M. T., Arrate, M. P., Ramsey, H. E., Sunthankar, K. I., Jenkins, M. T., Moyo, T. K., Smith, B. N., Fischer, M. A., Childress, M. A., Gorska, A. E., Ferrell, P. B., & Savona, M. R. (2021). The delta isoform of PI3K predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.

Chicago

Villaume, Matthew T., M. Pia Arrate, Haley E. Ramsey, Kathryn I. Sunthankar, Matthew T. Jenkins, Tamara K. Moyo, Brianna N. Smith, et al. 2021. “The Delta Isoform of PI3K Predominates in Chronic Myelomonocytic Leukemia and Can Be Targeted Effectively with Umbralisib and Ruxolitinib,” February. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........6e6d07272d9e40c96b10db5fcc2ad343&authtype=sso&custid=ns315887.